Rohit Thalla

Loyola University Medical Center — United States

Medicine · Health Sciences

5h-index341citations15works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(6), Immune cells in cancer(5), Neuroinflammation and Neurodegeneration Mechanisms(3), Epigenetics and DNA Methylation(2), Acute Myeloid Leukemia Research(2)

Publications15 total

Identification of a development-restricted, megakaryocyte-primed population of hematopoietic progenitor cells during fetal and early postnatal development
Blood·2025
CD27, CD62L and ESAM define a multipotent progenitor population with megakaryocytic potential
Blood·2025
TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice
Haematologica·2025Open Access
Advances and challenges in the treatment of myelodysplastic syndromes
Experimental Hematology and Oncology·2025· 3 citedOpen Access
Abstract 2103 Murine TBK1 regulates MPP3-type HSPCs and circulating leukocytes in normal hematopoiesis and FLT3+ LSCs in MLL-AF9-driven leukemia
Journal of Biological Chemistry·2025Open Access
Active STAT3 Prevents Selinexor-Induced Caspase-Independent Apoptosis in Multiple Myeloma
Blood·2023· 1 cited
Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy
ACS Nano·2022· 133 citedOpen Access
Murine brain tumor microenvironment immunophenotyping using mass cytometry
STAR Protocols·2022· 2 citedOpen Access
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy
Science Advances·2021· 87 citedOpen Access
Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy
2021· 1 citedOpen Access
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Frontiers in Pharmacology·2021· 84 citedOpen Access
TAMI-52. G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS, REVERSES THE MYELOID CELLS’-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
Neuro-Oncology·2020Open Access
G-CSF Secreted by Epigenetically Reprogrammed Mutant IDH1 Glioma Stem Cells Reverses the Myeloid Cells’-Mediated Immunosuppressive Tumor Microenvironment
2020· 3 citedOpen Access
Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1
2020· 6 citedOpen Access
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
Neuro-Oncology Advances·2020· 21 citedOpen Access

Frequent Co-authors

Mahmoud S. Alghamri(9), Pedro R. Löwenstein(9), María G. Castro(9), Ayman Taher(7), Ryan Mack(6), Peter Breslin(6), Brandon L. McClellan(5), Stephen V. Carney(5), Syed Mohd Faisal(5), Ruthvik Avvari(5), Jiwang Zhang(4), Kanak Joshi(4), Kaushik Banerjee(3), Anzar Mujeeb(3), Michael R. Olin(3), Santiago Haase(3), Maria Ventosa(3), Felipe J. Núñez(3), Daniel A. Orringer(3), Peter Ulintz(3)